No Data
No Data
Tianxin Pharmaceutical (603235.SH): has repurchased 0.5246% of its shares so far.
On July 31st, Gelunhui reported that Tianxin pharmaceutical (603235.SH) has repurchased 2.2967 million shares accumulatively as of July 31st, 2024, accounting for 0.5246% of the total share capital of the company. The highest repurchase price was 25.50 yuan/share and the lowest was 19.17 yuan/share. The total amount paid was 51.4045 million yuan (excluding transaction fees).
Do Its Financials Have Any Role To Play In Driving JiangXi Tianxin Pharmaceutical Co., Ltd.'s (SHSE:603235) Stock Up Recently?
Tianxin Pharmaceutical (603235.SH): Cumulative expenditure of 37.05 million yuan to repurchase 0.3949% of shares.
On July 1st, Gelunhui reported that as of June 30, 2024, the company had repurchased 1,728,768 shares, accounting for 0.3949% of the total share capital. The highest repurchase price was 24.00 yuan/share, the lowest price was 19.17 yuan/share, and the total amount paid was 37,053,396.56 yuan (excluding transaction fees).
Tianxin Pharmaceutical (603235.SH): The proportion of vitamin D3 business in the company's overall revenue is relatively small.
Tianxin Pharmaceutical (603235.SH) stated on the interactive platform on June 26 that the proportion of the company's overall revenue from vitamin D3 business is relatively small. Please refer to the company's periodic reports or related announcements for specific business information.
Tianxin Pharmaceutical (603235.SH) will distribute a dividend of 0.5 yuan per share for the year 2023, with a record date of June 25th.
Tianxin Pharmaceutical (603235.SH) announced that the company will implement the annual equity distribution for 2023, with a distribution of... per share.
We Think That There Are More Issues For JiangXi Tianxin Pharmaceutical (SHSE:603235) Than Just Sluggish Earnings
No Data